SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study

SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study

Abstract Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promise in reducing the risk of atrial fibrillation (AF). However, the results are controversial and the underlying metabolic mechanism remains unclear. Emerging evidence implied that SGLT2 inhibitors have extra benefic...

Full description

Bibliographic Details
Main Authors: Jiang Li, Yuefeng Yu, Ying Sun, Bowei Yu, Xiao Tan, Bin Wang, Yingli Lu, Ningjian Wang
Format: Article
Language:English
Published: BMC 2023-10-01
Series:Cardiovascular Diabetology
Subjects:
Atrial fibrillation
Sodium-glucose cotransporter 2 inhibition
Circulating metabolites
Mendelian randomization
Online Access:https://doi.org/10.1186/s12933-023-02019-8

Internet

https://doi.org/10.1186/s12933-023-02019-8

Similar Items